Current Status of Chemically Synthesized Inhibitors of Ebola Virus

Title:Current Status of Chemically Synthesized Inhibitors of Ebola Virus

Volume: 9 Issue: 2

Author(s): Anthony P. Cardile, Douglas L. Mayers and Sina Bavari

Affiliation:

Keywords: AVI-6002, AVI-7537, AVI-7539, BCX4430, brincidofovir, Ebola, favipiravir, TKM-100802.

Abstract: The current Ebola virus outbreak is unprecedented in its scope and international impact. Given that there are currently no approved antivirals to treat Ebola virus, there is urgency to conduct more rapid development and evaluation of Ebola antivirals. Recently, the World Health Organization identified a number of antivirals as high priority to include AVI-6002 (AVI-7537 and AVI-7539), BCX4430, brincidofovir, favipiravir, and TKM-100802. This review describes these chemically synthesized inhibitors of Ebola virus, relevant patent development and gives an update on their current status.

Cite this article as:

Cardile P. Anthony, Mayers L. Douglas and Bavari Sina, Current Status of Chemically Synthesized Inhibitors of Ebola Virus, Recent Patents on Anti-Infective Drug Discovery 2014; 9(2) . https://dx.doi.org/10.2174/1574891X10666150326114221